- Home
- GWRS vs CMPX Comparison
GWRS vs CMPX Comparison
Compare GWRS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- CMPX
- Stock Information
- Founded
- GWRS 2003
- CMPX 2014
- Country
- GWRS United States
- CMPX United States
- Employees
- GWRS N/A
- CMPX N/A
- Industry
- GWRS Water Supply
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- CMPX Health Care
- Exchange
- GWRS Nasdaq
- CMPX Nasdaq
- Market Cap
- GWRS 286.0M
- CMPX 291.8M
- IPO Year
- GWRS 2010
- CMPX N/A
- Fundamental
- Price
- GWRS $10.00
- CMPX $2.15
- Analyst Decision
- GWRS
- CMPX Strong Buy
- Analyst Count
- GWRS 0
- CMPX 8
- Target Price
- GWRS N/A
- CMPX $13.13
- AVG Volume (30 Days)
- GWRS 36.8K
- CMPX 790.1K
- Earning Date
- GWRS 05-14-2025
- CMPX 05-08-2025
- Dividend Yield
- GWRS 3.03%
- CMPX N/A
- EPS Growth
- GWRS N/A
- CMPX N/A
- EPS
- GWRS 0.23
- CMPX N/A
- Revenue
- GWRS $53,539,000.00
- CMPX $850,000.00
- Revenue This Year
- GWRS $7.63
- CMPX N/A
- Revenue Next Year
- GWRS $5.58
- CMPX N/A
- P/E Ratio
- GWRS $43.43
- CMPX N/A
- Revenue Growth
- GWRS 3.94
- CMPX N/A
- 52 Week Low
- GWRS $9.37
- CMPX $0.77
- 52 Week High
- GWRS $13.98
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- GWRS 41.88
- CMPX 60.21
- Support Level
- GWRS $9.95
- CMPX $2.06
- Resistance Level
- GWRS $10.22
- CMPX $2.23
- Average True Range (ATR)
- GWRS 0.23
- CMPX 0.12
- MACD
- GWRS -0.02
- CMPX 0.01
- Stochastic Oscillator
- GWRS 8.58
- CMPX 73.81
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.